|Articles|September 21, 2015

Follow us on Twitter!

Join @Clin_Trials on Twitter to keep up-to-date.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Why Execution Strategy Begins at the Business Decision, Not Study Startup

ByElizabeth Walsh, PMP, ACRP-CP,Andy Studna, Senior Editor

July 21st 2026

ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy

ByAndy Studna, Senior Editor

July 21st 2026

© putilov_denis - © putilov_denis - stock.adobe.com

Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology

ByAnna Pokorska-Bocci

July 20th 2026

The Quiet Misconception Behind Most Clinical Execution Failures

ByElizabeth Walsh, PMP, ACRP-CP,Andy Studna, Senior Editor

July 20th 2026

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

ByAndy Studna, Senior Editor

July 20th 2026

Follow us on Twitter!

Related Content

Why Execution Strategy Begins at the Business Decision, Not Study Startup

ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy

Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology

The Quiet Misconception Behind Most Clinical Execution Failures

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

Trending on Applied Clinical Trials Online

Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose

Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology

ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor

The Quiet Misconception Behind Most Clinical Execution Failures